ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million.

瑞士ROOT——（商业新闻短讯）——Novocure（纳斯达克代码：NVCR）今天宣布，它已与Pharmakon Advisors，LP管理的资金签订了一项新的五年期高达4亿美元的承诺性高级担保信贷安排。承诺资本将分四批提供给Novocure，金额为1亿美元。

The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes.

第一笔一亿美元在交割时发行，第二笔一亿美元将于2025年6月30日前发行。在2026年3月31日之前，根据Novocure的判断，并根据某些里程碑，另外两亿美元可分两期提取。这些收益将用于满足Novocure预计推出的非小细胞肺癌的营运资金需求，并在到期时结算Novocure的可转换票据。

Additional information on the agreement will be filed with the U.S. Securities and Exchange Commission as a Current Report on Form 10-Q..

有关该协议的其他信息将作为表格10-Q的最新报告提交给美国证券交易委员会。

“As we look ahead to multiple milestones on the horizon for Novocure, we have strengthened our cash position with non-dilutive capital and further solidified our balance sheet,” said Ashley Cordova, Novocure’s Chief Financial Officer. “This multi-tranche, delayed-draw, debt facility provides us with the flexibility and financial stability to invest in future growth, specifically in non-small cell lung cancer, as we execute our objectives and advance our clinical pipeline.

Novocure首席财务官阿什利·科尔多瓦（AshleyCordova）表示：“随着我们展望Novocure未来的多个里程碑，我们通过非稀释性资本加强了现金状况，并进一步巩固了资产负债表。”。“随着我们执行目标和推进临床流程，这种多批次、延迟提取的债务融资为我们提供了灵活性和财务稳定性，可以投资于未来的增长，特别是非小细胞肺癌。

We are pleased to again partner with Pharmakon on this transaction.”.

我们很高兴再次与Pharmakon合作完成这项交易。”

Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed $8.2 billion across 52 investments.

Pharmakon Advisors，LP是生命科学行业非稀释性债务的主要投资者，也是生物制药信贷基金的投资经理。成立于2009年，由Pharmakon Advisors，LP管理的基金在52项投资中承诺了82亿美元。

About Novocure

关于Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma.

Novocure是一家全球性肿瘤公司，致力于通过其创新疗法，肿瘤治疗领域的开发和商业化，延长一些最具侵袭性的癌症的生存期。Novocure的商业化产品在某些国家被批准用于治疗成人胶质母细胞瘤，恶性胸膜间皮瘤和胸膜间皮瘤患者。

Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer..

Novocure正在进行或完成临床研究，调查脑转移瘤，胃癌，胶质母细胞瘤，肝癌，非小细胞肺癌，胰腺癌和卵巢癌的肿瘤治疗领域。

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter..

Novocure总部位于瑞士Root，全球足迹不断扩大，在朴茨茅斯、新罕布什尔州和东京设有区域运营中心，在以色列海法设有研究中心。有关该公司的更多信息，请访问Novocure.com，并在LinkedIn和Twitter上关注@Novocure。

Forward-Looking Statements

前瞻性声明

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts.

除了历史事实或现状声明外，本新闻稿可能还包含前瞻性声明。前瞻性声明提供了Novocure目前对未来事件的预期或预测。这些可能包括关于其研究计划的预期科学进展、临床研究进展、潜在产品的开发、临床结果的解释、监管批准的前景、制造发展和能力、其产品的市场前景、覆盖范围、第三方付款人的收款以及其他关于非历史事实的陈述。

You may identify some of these forward-looking statements by the use of words in the statements such as “could,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S.

您可以通过在声明中使用诸如“可以”、“预期”、“估计”、“预期”、“项目”、“打算”、“计划”、“相信”或其他类似含义的词语和术语来识别其中一些前瞻性声明。由于一般的财务、经济、环境、监管和政治条件以及Novocure面临的其他更具体的风险和不确定性，Novocure的业绩和财务结果可能与这些前瞻性报表中反映的业绩和财务结果存在重大差异，如2024年2月22日提交的10-K表年度报告以及随后提交给美国。

Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law.

证券交易委员会。鉴于这些风险和不确定性，任何或所有这些前瞻性陈述可能被证明是不正确的。因此，您不应依赖任何此类因素或前瞻性陈述。此外，Novocure不打算公开更新任何前瞻性声明，除非法律要求。

Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion..

本文件中的任何前瞻性声明仅在本文件日期起生效。1995年的《私人证券诉讼改革法案》允许进行这种讨论。